Avalo Therapeutics, Inc.
AVTXNasdaq
$19.37
↑ +8.3%Jul 17 close · end-of-day
Price
1Y↑ +299.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$389.5M
Enterprise Value
$307.5M
P/E
—
P/S
—
P/B
5.7
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$84.7M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-124.0%
ROIC
—
Debt / Equity
—
Net Cash
$82.0M
Return 1Y
+242.2%
Company profile
Avalo Therapeutics, Inc. discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease and systemic juvenile idiopathic arthritis.
- CEO
- Garry A. Neil
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 40
- Headquarters
- Maryland
- Website
- avalotx.com
Management & directors
- Doyle MittieChief Medical Officer
- Riley JenniferChief Strategy Officer
- Sullivan Christopher RyanChief Financial Officer
- Varki PaulChief Legal Officer
- Neil Garry ArthurChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
AVTX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.98↓ -21.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $6.7M | $5.4M | $18.1M | $1.9M | $441,000.00 | $59,000.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$72.8M | -$82.1M | -$37.4M | -$27.4M | -$68.5M | -$72.9M |
| Net income | -$63.5M | -$84.4M | -$41.7M | -$31.5M | -$35.1M | -$78.3M |
| Diluted EPS | — | — | -$1,063.00 | -$113.58 | -$20.91 | -$5.84 |
| Operating cash flow | -$40.5M | -$70.9M | -$26.8M | -$30.7M | -$49.1M | -$51.5M |
| Free cash flow | -$40.6M | -$71.0M | -$26.8M | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -1087.4% | -1521.6% | -207.4% | -1421.6% | -15535.6% | -123601.7% |
| Net margin | -947.9% | -1563.1% | -230.8% | -1639.5% | -7965.8% | -132642.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $249,000.00 | $192,000.00 | — | — | $0.00 | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$9.6M | -$12.9M | -$13.3M | -$14.7M | -$19.3M | -$19.2M | -$19.7M | -$20.9M |
| Net income | $98.5M | $23.0M | -$35.3M | -$13.1M | -$20.8M | -$30.6M | -$13.7M | -$19.6M |
| Diluted EPS | -$14.07 | -$2.83 | $137.13 | -$1.25 | -$1.92 | -$2.19 | -$0.48 | -$0.98 |
| Operating cash flow | -$16.3M | -$11.5M | -$15.0M | -$9.5M | -$11.4M | -$16.4M | -$14.2M | -$17.7M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | -5165.1% | -6931.8% | — | — | — | — | — |
| Net margin | — | 9251.8% | -18405.7% | — | — | — | — | — |
Company news
Jul 7, 2026
Jun 26, 2026
Jun 23, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | Doyle Mittie· Chief Medical Officer | Sale | 4,654 | $20.00 | $93,080.00 | filing |
| 2026-06-30 | Doyle Mittie· Chief Medical Officer | Option exercise | 2,875 | $12.65 | $36,368.75 | filing |
| 2026-06-30 | Doyle Mittie· Chief Medical Officer | Option exercise | 1,779 | $8.04 | $14,303.16 | filing |
| 2026-06-23 | Doyle Mittie· Chief Medical Officer | Sale | 1,450 | $18.00 | $26,100.00 | filing |
| 2026-06-23 | Doyle Mittie· Chief Medical Officer | Option exercise | 1,450 | $8.04 | $11,658.00 | filing |
| 2026-06-10 | Doyle Mittie· Chief Medical Officer | Tax withholding | 1,084 | $13.10 | $14,200.40 | filing |
| 2026-06-10 | VARKI PAUL· Chief Legal Officer | Tax withholding | 1,081 | $13.10 | $14,161.10 | filing |
| 2026-06-10 | Riley Jennifer· Chief Strategy Officer | Tax withholding | 588 | $13.10 | $7,702.80 | filing |
| 2026-06-10 | Sullivan Christopher Ryan· Chief Financial Officer | Tax withholding | 138 | $13.10 | $1,807.80 | filing |
| 2026-05-28 | Doyle Mittie· Chief Medical Officer | Sale | 679 | $16.00 | $10,864.00 | filing |
| 2026-05-28 | Doyle Mittie· Chief Medical Officer | Option exercise | 679 | $8.04 | $5,459.16 | filing |
| 2026-05-21 | Riley Jennifer· Chief Strategy Officer | Award | 34,200 | $0.00 | $0.00 | filing |
| 2026-05-21 | Sullivan Christopher Ryan· Chief Financial Officer | Award | 39,900 | $0.00 | $0.00 | filing |
| 2026-05-21 | VARKI PAUL· Chief Legal Officer | Award | 24,300 | $0.00 | $0.00 | filing |
| 2026-05-21 | Doyle Mittie· Chief Medical Officer | Award | 43,500 | $0.00 | $0.00 | filing |
| 2026-05-21 | NEIL GARRY ARTHUR· Chief Executive Officer | Award | 100,200 | $0.00 | $0.00 | filing |
| 2026-05-15 | Doyle Mittie· Chief Medical Officer | Sale | 3,000 | $18.76 | $56,280.00 | filing |
| 2026-05-15 | Doyle Mittie· Chief Medical Officer | Option exercise | 3,000 | $12.65 | $37,950.00 | filing |
| 2026-05-07 | Sullivan Christopher Ryan· Chief Financial Officer | Sale | 18,606 | $24.12 | $448,817.65 | filing |
| 2026-05-07 | Sullivan Christopher Ryan· Chief Financial Officer | Option exercise | 18,606 | $9.88 | $183,827.28 | filing |
| 2026-05-06 | Doyle Mittie· Chief Medical Officer | Option exercise | 77,905 | $12.65 | $985,498.25 | filing |
| 2026-05-06 | Doyle Mittie· Chief Medical Officer | Sale | 44,944 | $21.20 | $952,668.98 | filing |
| 2026-05-06 | VARKI PAUL· Chief Legal Officer | Option exercise | 62,500 | $13.43 | $839,375.00 | filing |
| 2026-05-06 | VARKI PAUL· Chief Legal Officer | Sale | 37,375 | $18.91 | $706,836.00 | filing |
| 2026-05-06 | Doyle Mittie· Chief Medical Officer | Sale | 27,538 | $18.03 | $496,405.50 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.